News Coverage 10.20.20 Share on Twitter Share on Facebook Share on LinkedIn The international neoantigen initiative Tumour Neoantigen Selection Alliance (TESLA) has identified key parameters for immunotherapy advancement. Related Announcement, Press Release Parker Institute for Cancer Immunotherapy Names Maria Olson Chief Advancement Officer Announcement, Press Release PICI Invests $1 Million+ in 5 Early Career Researchers Announcement, Patient Story Living Proof: Cancer Vaccine Recipients Bring Their Sto
Announcement, Press Release Parker Institute for Cancer Immunotherapy Names Maria Olson Chief Advancement Officer